Yin Limei, Sun Ping, Guo Shujin, Shuai Ping, Zhang Junlin
Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189228. doi: 10.1016/j.bbcan.2024.189228. Epub 2024 Nov 29.
Small cell lung cancer (SCLC) is a devastating malignancy characterized by rapid metastasis, drug resistance, and frequent recurrence. Owing to the paucity of existing therapeutic options, the prognosis of SCLC remains poor. Recently, the combination of immune checkpoint inhibitors and chemotherapy has resulted in modest improvements in treatment responses. In this review, we characterize the biological signature of SCLC and outline the obstacles to current treatment, including impaired antigen presentation and T cell infiltration. These obstacles may potentially be overcome by chimeric antigen receptor (CAR)-T cell therapy. For the first time, we summarize the available data and discuss the future prospects of CAR-T cell therapy for the treatment of SCLC. Given the high heterogeneity and immunosuppressive tumor microenvironment of SCLC, structural modifications of CAR-T cells and combination therapy may be required to elicit a successful antitumor response. Further research, including clinical trials, is needed to determine the suitability of CAR-T cell therapy as a treatment for SCLC.
小细胞肺癌（SCLC）是一种具有快速转移、耐药性和频繁复发特征的毁灭性恶性肿瘤。由于现有治疗选择有限，SCLC的预后仍然很差。最近，免疫检查点抑制剂与化疗的联合应用在治疗反应方面取得了适度改善。在本综述中，我们描述了SCLC的生物学特征，并概述了当前治疗的障碍，包括抗原呈递受损和T细胞浸润。嵌合抗原受体（CAR）-T细胞疗法可能会克服这些障碍。我们首次总结了现有数据，并讨论了CAR-T细胞疗法治疗SCLC的未来前景。鉴于SCLC具有高度异质性和免疫抑制性肿瘤微环境，可能需要对CAR-T细胞进行结构修饰并联合治疗，以引发成功的抗肿瘤反应。需要进一步的研究，包括临床试验，来确定CAR-T细胞疗法作为SCLC治疗方法的适用性。
